Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial

被引：0

作者：

Abou-Alfa, G. K. ^{[1
]}

Borbath, I. ^{[2
]}

Clarke, S. J. ^{[3
]}

Hitre, E. ^{[4
]}

Louvet, C. ^{[5
]}

Macarulla, T. ^{[6
]}

Oh, D-Y. ^{[7
]}

Spratlin, J. L. ^{[8
]}

Valle, J. W. ^{[9
]}

Weiss, K. H. ^{[10
]}

Berman, C. ^{[11
]}

Howland, M. ^{[12
]}

Ye, Y. ^{[13
]}

Cho, T. ^{[14
]}

Moran, S. ^{[11
]}

Javle, M. M. ^{[15
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA

[2] Clin Univ St Luc Bruxelles, HepatoGastroenterol & Digest Oncol, Brussels, Belgium

[3] Univ Sydney, Med Oncol, Sydney, NSW, Australia

[4] Natl Inst Oncol, Med Oncol, Budapest, Hungary

[5] Inst Mutualiste Montsouris, Med Oncol, Paris, France

[6] Hosp Valle De Hebron, Med Oncol, Barcelona, Spain

[7] Seoul Natl Univ Hosp, Med Oncol, Seoul, South Korea

[8] Alberta Hlth Serv, Med Oncol, Edmonton, AB, Canada

[9] Univ Manchester, Med Oncol, Christie, Manchester, Lancs, England

[10] Univ Hosp Heidelberg, Transplant Hepatol, Heidelberg, Germany

[11] QED Therapeut Inc, Clin Dev, San Francisco, CA USA

[12] QED Therapeut Inc, Clin Sci, San Francisco, CA USA

[13] QED Therapeut Inc, Biostat, San Francisco, CA USA

[14] QED Therapeut Inc, Clin Operat, San Francisco, CA USA

[15] Univ Texas MD Anderson Canc Ctr, Med Oncol, Houston, TX 77030 USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

832TiP

引用

页数：2

共 50 条

[21] Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
Zhang, Li
Huang, Yan
Hong, Shaodong
Yang, Yunpeng
Yu, Gengsheng
Jia, Jun
Peng, Peijian
Wu, Xuan
Lin, Qing
Xi, Xuping
Peng, Jiewen
Xu, Mingjun
Chen, Dongping
Lu, Xiaojun
Wang, Rensheng
Cao, Xiaolong
Chen, Xiaozhong
Lin, Zhixiong
Xiong, Jianping
Lin, Qin
Xie, Conghua
Li, Zhihua
Pan, Jianji
Li, Jingao
Wu, Shixiu
Lian, Yingni
Yang, Quanlie
Zhao, Chong
LANCET, 2016, 388 (10054): : 1883 - 1892
[22] Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
Hirsch, L.
Le Tourneau, C.
ONCOLOGIE, 2017, 19 (1-2) : 44 - 46
[23] Eltrombopag plus diacerein vs eltrombopag in patients with ITP: a multicenter, randomized, open-label phase 2 trial
Sun, Lu
Huang, Xiaoyang
Wang, Juan
Yuan, Chenglu
Zhao, Hongyu
Li, Daqi
Xu, Ruirong
Wang, Yan
Qin, Ping
Shi, Yan
Peng, Jun
Hou, Ming
Hou, Yu
BLOOD, 2024, 144 (17)
[24] A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer
Schwartzberg, Lee S.
Arena, Francis P.
Bienvenu, Bryan J.
Kaplan, Edward H.
Camacho, Luis H.
Campos, Luis T.
Waymack, J. Paul
Tagliaferri, Mary A.
Chen, Michael M.
Li, Dapeng
JOURNAL OF CANCER, 2017, 8 (10): : 1872 - 1883
[25] Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors
Balmana, Judith
Tung, Nadine M.
Isakoff, Steven J.
Grana, Begona
Ryan, Paula D.
Rafi, Rezvan
Tracy, Michael
Winer, Eric
Baselga, Jose
Garber, Judy Ellen
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[26] Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement.
Bekaii-Saab, Tanios S.
Valle, Juan W.
Borad, Mitesh J.
Melisi, Davide
Vogel, Arndt
Feliz, Luis
Lihou, Christine Francis
Zhen, Huiling
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[27] Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer
Mazzanti, P
Massacesi, C
Rocchi, MBL
Mattioli, R
Lippe, P
Trivisonne, R
Buzzi, F
De Signoribus, G
Tuveri, G
Rossi, G
Di Lullo, L
Sturba, F
Morale, D
Catanzani, S
Pilone, A
Bonsignori, M
Battelli, T
LUNG CANCER, 2003, 41 (01) : 81 - 89
[28] Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
Javle, M.
Kelley, R. K.
Roychowdhury, S.
Weiss, K. H.
Abou-Alfa, G. K.
Macarulla, T.
Sadeghi, S.
Waldschmidt, D.
Zhu, A. X.
Goyal, L.
Borad, M.
Yong, W. P.
Borbath, I.
El-Khoueiry, A.
Philip, P.
Moran, S.
Ye, Y.
Ising, M.
Lewis, N.
Bekaii-Saab, T.
ANNALS OF ONCOLOGY, 2018, 29 : 720 - 720
[29] Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase lb and randomized, open-label, multicenter, phase 2 trial in Japan
Watanabe, Satoshi
Yoshioka, Hiroshige
Sakai, Hiroshi
Hotta, Katsuyuki
Takenoyama, Mitsuhiro
Yamada, Kazuhiko
Sugawara, Shunichi
Takiguchi, Yuichi
Hosomi, Yukio
Tomii, Keisuke
Niho, Seiji
Yamamoto, Nobuyuki
Nishio, Makoto
Ohe, Yuichiro
Kato, Terufumi
Takahashi, Toshiaki
Kamada, Ami
Suzukawa, Kazumi
Omori, Yukie
Enatsu, Sotaro
Nakagawa, Kazuhiko
Tamura, Tomohide
LUNG CANCER, 2019, 129 : 55 - 62
[30] An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer.
He, Jianxing
Shi, Yuankai
Chang, Jianhua
Wang, Mengzhao
Han, Baohui
Liu, Xiaoqing
Chen, Gongyan
Zhou, Caicun
Liu, Jiwei
Pan, Hongming
Huang, Cheng
Zhang, Shucai
Feng, Jifeng
Lin, Xiaoyan
Wang, Jie
Huang, Jianjin
Li, Fang
Qin, Shukui
Wang, Zhehai
Wang, Liwei
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →